Mar 11 2012
The German- Federal Institute for Drugs and Medical Devices (BfArM) has
granted Moberg Derma approval to initiate a clinical phase I trial for
Limtop. Limtop is an innovative formulation of an immunomodulatory
compound with potential to treat actinic keratosis, genital warts and
basal cell carcinoma. The objective is a product with short treatment
duration, an improved safety profile and an
efficacy similar to or
better than that of competing preparations.
"Limtop has the potential to make a real difference for many patients
who currently suffer significant side effects, and we are now looking
forward to test the formulation clinically. The results from the Phase I
study are expected in the second quarter of 2012", say Peter Wolpert,
CEO and founder of Moberg Derma.
Source Moberg Derma
New research sheds light on how GLP-1 obesity drugs may change food cravings